631 related articles for article (PubMed ID: 26541516)
1. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
[TBL] [Abstract][Full Text] [Related]
6. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
[No Abstract] [Full Text] [Related]
8. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
Abad Paniagua EJ; Casado Escribano P; Fernández Rodriguez JM; Morales Escobar FJ; Betegón Nicolás L; Sánchez-Covisa J; Brosa M
Aten Primaria; 2015 Oct; 47(8):505-13. PubMed ID: 25555492
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Van der Linden N; Van Olst S; Nekeman S; Uyl-de Groot CA
Diabet Med; 2021 Apr; 38(4):e14371. PubMed ID: 32745279
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Lasalvia P; Gil-Rojas Y; García Á
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):955-964. PubMed ID: 35259045
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
14. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
Bennett H; Tank A; Evans M; Bergenheim K; McEwan P
Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
Chin KL; Ofori-Asenso R; Si S; Hird TR; Magliano DJ; Zoungas S; Liew D
Sci Rep; 2019 Mar; 9(1):3256. PubMed ID: 30824788
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Am J Manag Care; 2019 May; 25(5):231-238. PubMed ID: 31120717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
